Compare DexCom, Inc. (DXCM) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ryanair Holdings plc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Ryanair Holdings plc trades at $54.24 (market cap $27.11B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.66% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Ryanair Holdings plc for 72 Days on average.
| DXCM | RYAAY | |
|---|---|---|
Market Cap | $31.86B | $27.11B |
Volume | 3,607,070 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $92.34 | $73.82 |
52-Week Low | $54.84 | $51.95 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | $31.32B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
RYAAY trades at $54.24, down 3.14% on the day, with a bearish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.43 and net income margin of 12.13%, but recent earnings have missed expectations. Cash flow turned negative in 2025, and the company faces headwinds from high fuel costs and Boeing MAX 10 certification delays, as reported by Reuters on September 29, 2026.
The outlook is mixed: valuation appears attractive, and analyst consensus is moderately bullish with 64.71% buy ratings, but near-term risks from oil price volatility and operational challenges pressure the stock. Investors should weigh strong profitability and market position against earnings volatility and external uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
